114 related articles for article (PubMed ID: 10514272)
1. High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2.
Xie XQ; Han XW; Chen JZ; Eissenstat M; Makriyannis A
J Med Chem; 1999 Oct; 42(20):4021-7. PubMed ID: 10514272
[TBL] [Abstract][Full Text] [Related]
2. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids.
Xie XQ; Eissenstat M; Makriyannis A
Life Sci; 1995; 56(23-24):1963-70. PubMed ID: 7776820
[TBL] [Abstract][Full Text] [Related]
3. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.
Reggio PH; Basu-Dutt S; Barnett-Norris J; Castro MT; Hurst DP; Seltzman HH; Roche MJ; Gilliam AF; Thomas BF; Stevenson LA; Pertwee RG; Abood ME
J Med Chem; 1998 Dec; 41(26):5177-87. PubMed ID: 9857088
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis.
Shim JY; Collantes ER; Welsh WJ; Subramaniam B; Howlett AC; Eissenstat MA; Ward SJ
J Med Chem; 1998 Nov; 41(23):4521-32. PubMed ID: 9804691
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist.
Zhang Q; Ma P; Iszard M; Cole RB; Wang W; Wang G
Drug Metab Dispos; 2002 Oct; 30(10):1077-86. PubMed ID: 12228183
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents.
Mazzoni O; Diurno MV; di Bosco AM; Novellino E; Grieco P; Esposito G; Bertamino A; Calignano A; Russo R
Chem Biol Drug Des; 2010 Jan; 75(1):106-14. PubMed ID: 19895505
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs).
Dutta AK; Ryan W; Thomas BF; Singer M; Compton DR; Martin BR; Razdan RK
Bioorg Med Chem; 1997 Aug; 5(8):1591-600. PubMed ID: 9313864
[TBL] [Abstract][Full Text] [Related]
8. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling.
Xie XQ; Pavlopoulos S; DiMeglio CM; Makriyannis A
J Med Chem; 1998 Jan; 41(2):167-74. PubMed ID: 9457240
[TBL] [Abstract][Full Text] [Related]
9. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding.
Aung MM; Griffin G; Huffman JW; Wu M; Keel C; Yang B; Showalter VM; Abood ME; Martin BR
Drug Alcohol Depend; 2000 Aug; 60(2):133-40. PubMed ID: 10940540
[TBL] [Abstract][Full Text] [Related]
10. WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction.
Shim JY; Howlett AC
J Chem Inf Model; 2006; 46(3):1286-300. PubMed ID: 16711748
[TBL] [Abstract][Full Text] [Related]
11. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
Hosohata Y; Quock RM; Hosohata K; Makriyannis A; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Feb; 321(1):R1-3. PubMed ID: 9083796
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
13. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.
Huffman JW; Mabon R; Wu MJ; Lu J; Hart R; Hurst DP; Reggio PH; Wiley JL; Martin BR
Bioorg Med Chem; 2003 Feb; 11(4):539-49. PubMed ID: 12538019
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
15. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.
Eissenstat MA; Bell MR; D'Ambra TE; Alexander EJ; Daum SJ; Ackerman JH; Gruett MD; Kumar V; Estep KG; Olefirowicz EM
J Med Chem; 1995 Aug; 38(16):3094-105. PubMed ID: 7636873
[TBL] [Abstract][Full Text] [Related]
16. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity.
Tao Q; McAllister SD; Andreassi J; Nowell KW; Cabral GA; Hurst DP; Bachtel K; Ekman MC; Reggio PH; Abood ME
Mol Pharmacol; 1999 Mar; 55(3):605-13. PubMed ID: 10051546
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens.
Pertwee RG; Griffin G; Lainton JA; Huffman JW
Eur J Pharmacol; 1995 Sep; 284(3):241-7. PubMed ID: 8666005
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats.
Tyler K; Hillard CJ; Greenwood-Van Meerveld B
Eur J Pharmacol; 2000 Dec; 409(2):207-11. PubMed ID: 11104836
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
20. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
